tetano
Editor, Senior Moderator
Arterioscler Thromb Vasc Biol
. 2020 Dec 3;ATVBAHA120315547.
doi: 10.1161/ATVBAHA.120.315547. Online ahead of print.
Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality
Axel Rosell[SUP] #[/SUP][SUP] 1 [/SUP], Sebastian Havervall[SUP] #[/SUP][SUP] 1 [/SUP], Fien von Meijenfeldt[SUP] 2 [/SUP], Yohei Hisada[SUP] 3 [/SUP], Katherina Aguilera[SUP] 1 [/SUP], Steven P Grover[SUP] 3 [/SUP], Ton Lisman[SUP] 2 [/SUP], Nigel Mackman[SUP] #[/SUP][SUP] 3 [/SUP], Charlotte Th?lin[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
Abstract
Objective: Patients with coronavirus disease 2019 (COVID-19) have a high rate of thrombosis. We hypothesized that severe acute respiratory syndrome coronavirus 2 leads to induction of TF (tissue factor) expression and increased levels of circulating TF-positive extracellular vesicles (EV) that may drive thrombosis. Approach and Results: We measured levels of plasma EV TF activity in 100 patients with COVID-19 with moderate and severe disease and 28 healthy controls. Levels of EV TF activity were significantly higher in patients with COVID-19 compared with controls. In addition, levels of EV TF activity were associated with disease severity and mortality. Finally, levels of EV TF activity correlated with several plasma markers, including D-dimer, which has been shown to be associated with thrombosis in patients with COVID-19.
Conclusions: Our results indicate that severe acute respiratory syndrome coronavirus 2 infection induces the release of TF-positive EVs into the circulation that are likely to contribute to thrombosis in patients with COVID-19. EV TF activity was also associated with severity and mortality.
Keywords: COVID-19; coronavirus; extracellular vesicles; fibrinogen; thrombosis.
. 2020 Dec 3;ATVBAHA120315547.
doi: 10.1161/ATVBAHA.120.315547. Online ahead of print.
Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality
Axel Rosell[SUP] #[/SUP][SUP] 1 [/SUP], Sebastian Havervall[SUP] #[/SUP][SUP] 1 [/SUP], Fien von Meijenfeldt[SUP] 2 [/SUP], Yohei Hisada[SUP] 3 [/SUP], Katherina Aguilera[SUP] 1 [/SUP], Steven P Grover[SUP] 3 [/SUP], Ton Lisman[SUP] 2 [/SUP], Nigel Mackman[SUP] #[/SUP][SUP] 3 [/SUP], Charlotte Th?lin[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
- PMID: 33267656
- DOI: 10.1161/ATVBAHA.120.315547
Abstract
Objective: Patients with coronavirus disease 2019 (COVID-19) have a high rate of thrombosis. We hypothesized that severe acute respiratory syndrome coronavirus 2 leads to induction of TF (tissue factor) expression and increased levels of circulating TF-positive extracellular vesicles (EV) that may drive thrombosis. Approach and Results: We measured levels of plasma EV TF activity in 100 patients with COVID-19 with moderate and severe disease and 28 healthy controls. Levels of EV TF activity were significantly higher in patients with COVID-19 compared with controls. In addition, levels of EV TF activity were associated with disease severity and mortality. Finally, levels of EV TF activity correlated with several plasma markers, including D-dimer, which has been shown to be associated with thrombosis in patients with COVID-19.
Conclusions: Our results indicate that severe acute respiratory syndrome coronavirus 2 infection induces the release of TF-positive EVs into the circulation that are likely to contribute to thrombosis in patients with COVID-19. EV TF activity was also associated with severity and mortality.
Keywords: COVID-19; coronavirus; extracellular vesicles; fibrinogen; thrombosis.